GlassScriptPhysician profile
Tina D Malonson
NPI 1902437270
$6,403.36
in general payments reported to CMS, 2019-2025
19 companies · $3,198 in 2025
The $3,198 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $100 · 2022: $550 · 2023: $539 · 2024: $2,016 · 2025: $3,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,753.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $1,332.44 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $852.06 | 2024-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $747.41 | 2022-2025 | Caplyta |
| Abbvie INC. | $489.35 | 2023-2025 | |
| Gilead Sciences, INC. | $397.45 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $396.58 | 2025 | Fanapt |
| Alkermes, INC. | $362.30 | 2023-2025 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $331.80 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $270.26 | 2025 | Cobenfy |
| Corium, LLC | $209.42 | 2022-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $199.60 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Braeburn INC. | $152.65 | 2024-2025 | Brixadi |
| Amgen INC. | $135.00 | 2025 | Krystexxa |
| Phathom Pharmaceuticals, INC. | $123.99 | 2025 | Voquezna |
| Alexion Pharmaceuticals, INC. | $113.71 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $100.00 | 2025 | |
| Indivior INC. | $87.59 | 2024-2025 | Sublocade |
| Lilly USA, LLC | $86.78 | 2025 | Zepbound |
| Collegium Pharmaceutical, INC. | $14.97 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tina Malonson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.